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Purpose/Objective: Available clinical tumour response data 
originate predominantly from homogeneous dose irradiation 
while local failure patterns were often found to be non-
homogeneously distributed in the target volume. 
Consequently, scenarios to boost the dose in high-risk regions 
have been proposed that need to be modelled 
appropriately.We propose a simple and general method to 
estimate the tumour control probability (TCP) for boost 
scenarios only based on clinical data from homogeneous dose 
prescriptions. We demonstrate its applicability for a planning 
study on 42 patients with a simultaneous integrated boost 
(SIB) for photon and proton irradiation. 
Materials and Methods: We derived a simple formalism to 
analytically determine pairs of the TCP parameters D50 (dose 
at 50% TCP) and γ50 (slope of TCP at D50) for each tumour sub-
volume according to its observed local failure probability f 
based on assumptions made by Vogelius et al. [Med.Phys. 40, 
81717, 2013]. For the case of one high-risk (H) and one low-
risk (L) tumour sub-volume the two pairs of TCP parameters 
are found to be 
 
 
They only require knowledge of clinically obtained TCP data 
D50 and γ50 for homogeneous irradiation while the parameters 
A, B, C and D depend exclusively on f. The slope is chosen to 
be the same for each sub-volume. By construction the 
product of all sub-volume TCP curves reproduces the original 
TCP curve for a homogeneous irradiation of the whole 
volume. We applied this TCP modelling approach to 42 
advanced stage head and neck cancer patients included in a 
planning study comparing four SIB scenarios per patient: two 
dose levels (2.3 Gy and 2.6 Gy), each for photon and for 
proton irradiation. A radioresistant model with D50 = 83.35 Gy 
and γ50 = 0.97 was assumed together with relative failure 
probabilities of f = 0.8 in the gross tumour volume (GTV) and 
f = 0.2 in the clinical tumour volume (CTV). 
Results: Applying the derived formulae to these input data 
yields DH50 = 75.0 Gy for the GTV and DL50 = 50.0 Gy for the 
CTV. The slope is γH/L50 = 0.70. TCP results for all four SIB 
schemata are shown in the figure for the GTV, CTV and their 
product, i.e. total TCP, including all 42 patients. The photon 
(X) and proton (P) TCP do not differ significantly despite 
higher doses for photon plans in a rim around the SIB volume. 
Dose escalation from a 2.3 Gy to a 2.6 Gy SIB resulted in an 
estimated 15 % relative increase in the median TCP from 0.42 
to 0.485, respectively. TCP modelling assuming only a single 
homogeneous dose response leads to lower total TCP and 
significant TCP differences between photon and proton plans 
for the same dose prescription. 
 
 
 
 
Conclusions: We proposed a formalism to model tumour 
response in boost scenarios which is useful for three reasons: 
It a) is given by a simple analytical expression, b) depends 
only on clinical data and c) can be applied to different 
tumour types and boost scenarios. 
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Purpose/Objective: A risk of radiation-induced cancer, 
particularly in directly irradiated tissues such as the bladder 
and rectum, has been observed in patients after prostate 
radiotherapy (RT). Risks rising to as high as 1 in 70 have been 
observed based on more than ten year follow-up of patients 
treated with older radiation techniques [Murray et al, 2014]. 
Proton therapy has a considerable potential to reduce 
integral doses with similar or improved high-dose conformity 
compared to advanced photon therapy. The aim of this study 
was to use theoretical risk models to predict how these 
characteristics of photons and protons would influence the 
risk of radiation-induced cancer to the bladder and rectum 
after RT of prostate cancer. 
Materials and Methods: Simultaneously integrated boost 
treatment plans were generated for ten prostate patients 
using both volumetric modulated arc therapy (VMAT) and 
intensity-modulated proton therapy (IMPT). Both VMAT and 
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IMPT plans were prescribed to deliver 67.5 Gy to the prostate 
and 60 Gy to the seminal vesicles over 25 fractions. In the 
case of IMPT, corresponding doses were prescribed as 
Gy(RBE). The dosimetric and volumetric distributions for each 
treatment plan were evaluated with respect to risk of 
radiation-induced cancer by using both the linear-no-
threshold (LNT) model and the non-linear competitive risk 
model which incorporates cell killing vs induction of 
carcinogenic mutations in fractionated RT [Dasu et al, 2005]. 
The organ equivalent dose (OED) concept [Schneider et al, 
2005] was adapted to both risk-response models and served 
as a relative risk measure, while estimates of absolute risks 
were based on five nominal risk calculation methods of 
organ-specific radiation induced cancer as suggested by the 
International Commission on Radiological Protection [ICRP 
103, 2007]. 
Results: All treatment plans fulfilled the plan optimisation 
criteria as defined by standardised treatment protocols. The 
IMPT generally achieved a lower integrated dose to healthy 
tissues (Figure 1), and mean doses to the bladder and rectum 
were reduced as well as the percentage of the volumes 
receiving 20 Gy and 40 Gy. The linear risk models compared 
in favour of IMPT for both organs at risk (Table 1). The 
corresponding results using the competition model resulted in 
a 1.7 times higher risk of bladder cancer from VMAT 
compared to IMPT, while no significant difference was seen 
between the two techniques for the rectum. Translating the 
relative scoring from the competition model into absolute 
quantities, the risks for VMAT and IMPT were 0.2-0.5 % and 
0.1-0.3 %, respectively. The risks of radiation induced rectal 
cancer were estimated to 0.1-0.3 % for both radiation 
modalities. 
 
 
 
Conclusions: When incorporating effects of non-linear dose-
response and fractionated RT, VMAT resulted in 1.7 times 
higher risk of radiation-induced bladder cancer compared to 
IMPT, while no significant difference between the two 
techniques was found for secondary rectal cancer. 
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Purpose/Objective: Hodgkin's lymphoma (HL) radiation 
treatments may be responsible for late-phase subclinical lung 
radiation-induced injury such as fibrosis with radiological 
lung density changes detectable by computed tomography 
(CT). Using a machine-learning technique, our purpose was to 
investigate variable importance in predicting radiation-
induced CT changes in HL survivors treated with 
chemotherapy and radiotherapy (RT). The potential role of 
heart irradiation on the risk of CT changes was also 
investigated. 
Materials and Methods: One hundred ten consecutive 
patients treated with sequential chemo-radiotherapy for 
supradiaphragmatic HL (median follow-up 68 months, range 
13-140) were retrospectively reviewed for radiological signs 
of lung CT changes. All patients were treated with three-
dimensional conformal radiotherapy with a median total dose 
of 30.6 Gy (range 14.4-45). At a median time of 16.5 months 
(range 6-102), 18 of 110 patients (16.4%) developed lung 
